Shandong Weigao Blood Purification Products Co (SHSE:603014) Retained Earnings: ¥2,020 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603014 Shandong Weigao Blood Purification Products Co Ltd SHSE:603014
39 GF Score
Price ¥31.47
! 3 Warning Signs
View Full Analysis

What is Shandong Weigao Blood Purification Products Co Retained Earnings?

Shandong Weigao Blood Purification Products Co SHSE:603014 +0.77% 39 Retained Earnings is ¥2,020 Mil as of Jun. 2026. GuruFocus rates SHSE:603014 with a GF Score™ of 39/100. The stock has 3 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Shandong Weigao Blood Purification Products Co's retained earnings for the quarter that ended in Jun. 2026 was ¥2,020 Mil.

Shandong Weigao Blood Purification Products Co's quarterly retained earnings increased from Dec. 2025 (¥1,734 Mil) to Mar. 2026 (¥1,852 Mil) and increased from Mar. 2026 (¥1,852 Mil) to Jun. 2026 (¥2,020 Mil).

Shandong Weigao Blood Purification Products Co's annual retained earnings increased from Dec. 2023 (¥917 Mil) to Dec. 2024 (¥1,326 Mil) and increased from Dec. 2024 (¥1,326 Mil) to Dec. 2025 (¥1,734 Mil).


Shandong Weigao Blood Purification Products Co  (SHSE:603014) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Shandong Weigao Blood Purification Products Co Retained Earnings Historical Data

* Premium members only.

The historical data trend for Shandong Weigao Blood Purification Products Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Weigao Blood Purification Products Co Retained Earnings Chart

Shandong Weigao Blood Purification Products Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial 319.24 522.21 917.38 1,325.97 1,733.92

Shandong Weigao Blood Purification Products Co Quarterly Data
Sep24 Mar25 Sep25 Dec25 Mar26 Jun26
Retained Earnings Get a 7-Day Free Trial - 1,600.92 1,733.92 1,852.23 2,019.99
SHSE:603014
39GF Score
Shandong Weigao Blood Purification Products Co Ltd SHSE:603014
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shandong Weigao Blood Purification Products Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of ¥2,020 Mil mean?
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a Retained Earnings of ¥2,020 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Shandong Weigao Blood Purification Products Co and its competitors.
Is Shandong Weigao Blood Purification Products Co's Retained Earnings too high?
Shandong Weigao Blood Purification Products Co's current Retained Earnings is ¥2,020 Mil. Overall, Shandong Weigao Blood Purification Products Co has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Weigao Blood Purification Products Co's Retained Earnings compare to ABT and SYK?
Shandong Weigao Blood Purification Products Co's Retained Earnings of ¥2,020 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Devices & Instruments company?
A good Retained Earnings depends on the Medical Devices & Instruments industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. Shandong Weigao Blood Purification Products Co's current Retained Earnings is ¥2,020 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Weigao Blood Purification Products Co stock overvalued right now?
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a current Retained Earnings of ¥2,020 Mil. The current Retained Earnings is ¥2,020 Mil. Shandong Weigao Blood Purification Products Co's overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Shandong Weigao Blood Purification Products Co (SHSE:603014), the current Retained Earnings is ¥2,020 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shandong Weigao Blood Purification Products Co Business Description

Address No. 7, Weigao West Road, Torch High-tech Industrial Development Zone, Shandong Province, Weihai, CHN, 264200
Shandong Weigao Blood Purification Products Co Ltd engaged in research and development, production and sales of blood purification medical products.
39GF Score

Get the complete analysis for SHSE:603014

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥31.47
Price